SCHEMBL171415

SCHEMBL171415

COc1ccc(NC(C)=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.73
NPC1 O15118 3/20 0.73
RAB9A P51151 3/20 0.73
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
MAPT P10636 2/20 0.68
HTT P42858 2/20 0.68
ALDH1A1 P00352 1/20 0.68
HSD17B10 Q99714 1/20 0.68
MTNR1A P48039 2/20 0.67
MTNR1B P49286 2/20 0.67
IDO1 P14902 1/20 0.66
TP53 P04637 1/20 0.66
ALOX15 P16050 1/20 0.66
LMNA P02545 1/20 0.63
CYP1A2 P05177 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
L3MBTL1 Q9Y468 2/20 0.61
TGM2 P21980 1/20 0.61
POLB P06746 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9571811 0.94 MTNR1A (0.71) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL14384396 0.94 MTNR1A (0.76) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3468387 0.91 MAPT (0.68) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6814406 0.91 CYP1A2 (0.69) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL11481934 0.91 IDO1 (0.66) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL18409069 0.89 NPC1 (0.67) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL10926166 0.89 NPC1 (0.59) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL13728829 0.88 IDO1 (0.71) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL10923463 0.86 IDO1 (0.57) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3185469 0.86 MEN1 (0.63) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115650912-B 2-Mercapto-6-methoxyquinoline-3-formaldehyde-N-oxide and synthetic method and application thereof 灌南森迪门业有限公司 2024-09-06 CN claimed
CN-118344264-A 13Purification method of C Mexaxetine13C Meishasistine 北京华亘安邦科技有限公司 2024-07-16 CN claimed
US-20240207453-A1 13C METHACETIN GRANULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING RICHEN-FORCE SCIENCE & TECHNOLOGY CO., LTD (CN) 2024-06-27 US claimed
CN-114681446-B Application of acetamide compound as glutamate dehydrogenase inhibitor 南京盛德生物科技研究院有限公司 2024-05-10 CN claimed
CN-117772103-A Preparation device and preparation method of 3-nitro-4-methoxy acetanilide 杭州吉华江东化工有限公司 2024-03-29 CN claimed
CN-117777029-A Production method of omeprazole pharmaceutical intermediate 2-mercapto-5-methoxybenzimidazole 上海卓鼎生物技术有限公司 2024-03-29 CN claimed
EP-4327805-A1 13C METHACETIN GRANULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Richen-Force Science & Technology Co., Ltd (CN) 2024-02-28 EP claimed
CN-115583894-B Method and device for continuously producing 2-nitro-4-methoxy acetanilide 浙江迪邦化工有限公司 2024-02-27 CN claimed
US-20230282357-A1 ACUTE LIVER PATIENT MANAGEMENT Meridian Bioscience Israel Ltd. (IL) 2023-09-07 US claimed
CN-116688160-A The method comprises the following steps of 13 C-mexacetin orally disintegrating tablet as well as preparation method and application thereof 北京华亘安邦科技有限公司 2023-09-05 CN claimed
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2002-08-08 US claimed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US claimed
WO-2002024701-A2 SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO claimed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO claimed
EP-0913161-A2 Diagnostic agent for diabetes Tokyo Gas Co., Ltd. (JP) 1999-05-06 EP claimed
EP-0701558-A1 PROCESS OF MAKING SPIROCYCLES AND ANALOGS THEREOF MERCK & CO. INC. (US) 1996-03-20 EP claimed
WO-1994029317-A1 PROCESS OF MAKING SPIROCYCLES AND ANALOGS THEREOF MERCK & CO., INC. (US) 1994-12-22 WO claimed
US-4285863-A YELLOW-TO-RED ORGANIC PIGMENTS; PLASTICS AND FABRICS; PAINTS, ENAMELS, AND INKS MONTEDISON S.P.A. (IT) 1981-08-25 US claimed
US-4139558-A Process for preparing free-flowing 2-nitro-4-acetylamino-anisole BAYER AKTIENGESELLSCHAFT (DE) 1979-02-13 US claimed
US-3952129-A AROMATIC SECONDARY AMINE FUJI PHOTO FILM CO., LTD. (JA) 1976-04-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E SMN1; SMN2 1296/4885NPC1 1345/4885RAB9A 698/4885
US-20240207453-A1 13C METHACETIN GRANULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF GOT2, GOT1, CYP4F11 SMN1; SMN2 3310/4885NPC1 1781/4885RAB9A 1420/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 SMN1; SMN2 1106/4885NPC1 1176/4885RAB9A 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.